© 2020 MJH Life Sciences and Practical Cardiology. All rights reserved.
© 2020 MJH Life Sciences™ and Practical Cardiology. All rights reserved.
September 27, 2020
Gregory Weiss, MD, reflects on the idea of creating a cardiometabolic subspecialty.
September 12, 2020
Data from more than 4500 diabetics suggest CAC was better at predicting CVD and all-cause mortality in women than in men.
September 09, 2020
A study from ESC Congress 2020 dove deeper into associations between specific biomarkers and risk of CV events in CAD patients with and without diabetes.
September 07, 2020
Dr. Gregory Weiss compiles thoughts and perspective on hot line trials presented at ESC Congress 2020.
September 03, 2020
Milton Packer, MD, discusses how EMPEROR-Reduced data influences the way clinicians view the SGLT2 inhibitor class and its uses.
August 30, 2020
Full results of the DAPA-CKD trial from ESC Congress 2020 detail the effects of dapagliflozin (Farxiga) among chronic kidney disease patients with and without type 2 diabetes.
August 29, 2020
Results of the phase 3 EMPEROR-Reduced trial indicate the SGLT2 inhibitor empagliflozin was effective for patients with HFrEF regardless of whether the patients had diabetes or not.
August 15, 2020
An analysis of more than 20 studies and 70k patients details the impact cardiovascular risk factors and complications can have on outcomes in patients hospitalized with COVID-19.
August 10, 2020
An analysis of patient data from Europe suggests an increased number of infections requiring antibiotic use was tied to an elevated risk of coronary heart disease in type 1 diabetics.
August 01, 2020
A practicing endocrinologist discusses his reaction to topline results from EMPEROR-REDUCED and what he hopes to see in the presentation at ESC 2020.